Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 15.5% in June

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 23,500 shares, a drop of 15.5% from the May 31st total of 27,800 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 194,300 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ACHL shares. Piper Sandler reiterated a “neutral” rating and set a $2.00 price target (down from $8.00) on shares of Achilles Therapeutics in a research report on Friday, April 5th. Chardan Capital reduced their price target on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, April 5th.

Institutional Trading of Achilles Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ACHL. Fcpm Iii Services B.V. purchased a new stake in Achilles Therapeutics in the 4th quarter worth approximately $2,127,000. Ikarian Capital LLC purchased a new stake in shares of Achilles Therapeutics during the 1st quarter valued at $1,804,000. StemPoint Capital LP purchased a new stake in shares of Achilles Therapeutics during the 1st quarter valued at $1,732,000. Acadian Asset Management LLC purchased a new stake in shares of Achilles Therapeutics during the 1st quarter valued at $350,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Achilles Therapeutics during the 4th quarter valued at $96,000. 56.38% of the stock is owned by hedge funds and other institutional investors.

Achilles Therapeutics Price Performance

Shares of Achilles Therapeutics stock opened at $0.82 on Monday. Achilles Therapeutics has a 1 year low of $0.74 and a 1 year high of $1.76. The company has a market capitalization of $33.49 million, a P/E ratio of -0.51 and a beta of 1.35. The business has a 50 day moving average price of $0.87 and a 200 day moving average price of $0.97.

Achilles Therapeutics (NASDAQ:ACHL) last released its earnings results on Wednesday, May 8th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.16. As a group, research analysts expect that Achilles Therapeutics will post -1.26 EPS for the current fiscal year.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.